Sartorius Stedim Biotech Expands PAT Software Portolio for Optimization of Biopharmaceutical Development and Manufacturing Processes
Sartorius Stedim Biotech (SSB), a leading international pharmaceutical and biotech supplier, has entered into a global sales partnership with Umetrics AB, a Swedish software manufacturer.
Goettingen, Germany, December 18, 2012 / B3C newswire / – Sartorius Stedim Biotech (SSB), a leading international pharmaceutical and biotech supplier, has entered into a global sales partnership with Umetrics AB, a Swedish software manufacturer. Umetrics is a highly specialized, leading provider of chemometrics software worldwide for modeling and optimizing biopharmaceutical development and manufacturing processes.
The cooperation agreement provides that SSB will assume global marketing and distribution of the complete Umetrics portfolio for the pharmaceutical and biopharmaceutical industries. SSB will integrate Umetrics software programs as private label products into its own bioprocess portfolio and market these as stand-alone solutions under both brands under a dual branding arrangement. Stefan Schlack, Senior Vice President of Marketing at SSB commented: “These software solutions will help our customers to better understand their cell culture processes and to identify potential for optimization and robust process control – an ideal addition to our bioprocess portfolio.”
The major areas of application for these software systems are critical process steps, such as cell culture processes or specific purification steps in the biopharmaceutical industry. Multivariate data analysis (MVA) enables all process parameters to be added in batch trajectories, among other things, so that process variations and their causes can be displayed transparently in real time. DoE software (Design of Experiments) permits these critical process parameters to be efficiently identified and quantified and development cycles to be considerably shortened.
Umetrics stands to benefit from the global sales structures of SSB. “With SSB, we can gain access to substantially more customers thanks to its international reach and solid market standing in the biopharma sector. SSB’s integrated solutions for the complete biopharmaceutical process clearly create added value for our customers. I anticipate that this will considerably boost the biopharmaceutical industry’s interest in and usage of our products,” says Lars Lindstorm, General Manager of Umetrics.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...